Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Supply of Anapeine Generic to Start by Year-End: Minister
As a supply crunch continues for Sandoz’s long-acting local anesthetic Anapeine (ropivacaine) in Japan, its generic version is expected to reach the market before the end of the year, Health Minister Takamaro Fukuoka said on October 8. Anapeine has been…
To read the full story
Related Article
- Terumo Puts Brake on Supply of Anapeine Generics
November 21, 2024
- Terumo Rolls Out Anapeine Generics after Expedited Listing
November 13, 2024
- Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
- Sandoz Gives Update on Anapeine Supply after Manufacturing Change
October 30, 2024
- Local Anesthetic Supply Won’t Recover Soon Despite New Site Approval: Specialist
October 28, 2024
- Sandoz Japan Gets OK to Add New Manufacturing Site for Anapeine
October 15, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
- Local Anesthetic Runs Short in Japan Due to Curbed Supply of Sandoz’ Anapeine
July 31, 2024
REGULATORY
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
- Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
- LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026
- Lower House Clears Immunization Act Revision
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…